tiropramide 100	octylonium 20 mg	the degree of symptom reduction in abdominal pain using symptom diaries from week 1 	15709	15883	Furthermore, the degree of symptom reduction in abdominal pain using symptom diaries was higher in the tiropramide group than in the octylonium group from week 1 (P = 0.033).
tiropramide 100	octylonium 20 mg	Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL	1497	1659	Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL were also improved by both treatments, and the changes from baseline did not differ.
tiropramide 100	octylonium 20 mg	The VAS scores of abdominal pain at week 4	1263	1455	The VAS scores of abdominal pain at week 4, were significantly decreased in both tiropramide and octylonium groups, but the change from baseline did not differ between the 2 groups (difference
tiropramide 100	octylonium 20 mg	The VAS scores of abdominal pain at week 4	1473	1496	-4.33-3.82; P = 0.901).
tiropramide 100	octylonium 20 mg	Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL	1456	1472	-0.26 mm; 95% CI
tiropramide 100	octylonium 20 mg	The VAS scores of abdominal pain at week 4	1456	1472	-0.26 mm; 95% CI
tiropramide 100	octylonium 20 mg	The incidence of adverse events	1660	1786	The incidence of adverse events was similar in the 2 groups, and no severe adverse events involving either drug were observed.
tiropramide 100	octylonium 20 mg	Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL	1263	1455	The VAS scores of abdominal pain at week 4, were significantly decreased in both tiropramide and octylonium groups, but the change from baseline did not differ between the 2 groups (difference
tiropramide 100	octylonium 20 mg	Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL	1473	1659	-4.33-3.82; P = 0.901). Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL were also improved by both treatments, and the changes from baseline did not differ.
